Articles

FDA Delays Decision on AstraZeneca Breast Cancer Pill: What It Means

The FDA has postponed its decision on AstraZeneca's breast cancer pill, raising questions about the drug's future. This article explores the implications for the pharmaceutical industry.

NSF Pharma Biotech Conference 2026 Insights

The NSF's fourth annual Pharma Biotech Conference 2026 will address critical developments in clinical trials. This article provides key insights and implications for business development teams, investors, and analysts.

Biotech IPOs Surge Amid Pharma M&A Activity

The biotech landscape is witnessing a resurgence in IPOs, driven by a wave of mergers and acquisitions. This article analyzes the implications for investors and pharma teams.

FDA Calendar 2026: PDUFA Dates and Approvals

This article outlines the upcoming FDA approval dates and PDUFA deadlines for 2026, providing essential insights for investors and analysts in the biopharma sector.

Oligonucleotide Therapeutics Market Outlook to 2033

This article provides an in-depth analysis of the Oligonucleotide Therapeutics market size for 2033, focusing on clinical trials and their implications for stakeholders.

CordenPharma Expands Production Capacity with New CDMO Deal

CordenPharma's recent partnership with a peptide CDMO marks a significant expansion in GLP-1 production. This strategic move aims to bolster their manufacturing footprint in key markets.

Potential FDA Approval for Eye Drug: What It Means for Pharma

The FDA's recent appeal win for a thrice-snubbed eye drug signals a potential approval on the horizon. This article explores the implications for the pharmaceutical industry.

Trump's Medical Exam: Implications for the Pharmaceutical Industry

Trump's recent declaration of a 'perfect' medical exam raises questions about health perceptions and pharmaceutical impacts. This article explores the implications for the industry.

Opportunities in US Healthcare Amid Pricing Pressures

This article explores the vast opportunities in US healthcare and life sciences amidst current policy and pricing challenges, based on recent survey findings.

AstraZeneca's Breast Cancer Pill and ADAP Deal Insights

This article covers AstraZeneca's latest breast cancer pill developments and an ADAP deal in Florida, highlighting key implications for the pharmaceutical industry.

Johnson & Johnson's Strategic Shift: Layoffs in New Jersey

Johnson & Johnson is laying off 56 employees in New Jersey as it separates from its orthopedics business, signaling a strategic shift in operations.

Kailera Triple-G Shot Posts Early Weight Loss

Kailera's three-pronged obesity shot demonstrates promising results in early trials, indicating significant potential for market impact. This article explores the implications for pharmaceutical stakeholders.

STAT+: Disagreement Between Patients and Hospitals on AI

This article delves into the contrasting views of patients and hospitals regarding AI in healthcare, highlighting key insights and implications for the pharmaceutical industry.

Sen. Dick Durbin: Trump is Letting Big Tobacco Target Children

Sen. Dick Durbin raises concerns over Trump's policies enabling Big Tobacco to market to children. This article explores the implications for the pharmaceutical industry.

The Demand for Unvaccinated Blood Transfusions: A Growing Concern

As patients increasingly request unvaccinated blood transfusions, the pharmaceutical industry must navigate the implications for public health and regulatory compliance.

Stanford Patients Illuminate Health AI Adoption Challenges

This article discusses how patient feedback at Stanford is uncovering significant challenges in the adoption of health AI technologies, impacting pharma strategies.

Are We Just Going to Give Up and Die Like Every Other Generation?

This article explores the evolving longevity movement and its potential impact on the pharmaceutical industry, addressing the pressing question of generational health.

FDA Delays Ruling on AstraZeneca’s Breast Cancer Drug: Implications for Pharma

The FDA's delay on AstraZeneca's breast cancer drug ruling raises significant questions for the pharmaceutical industry. This article explores the implications for investors and pharma teams.

The End of Science as We Know It: Implications for Pharma

This article examines the current state of science and its implications for the pharmaceutical industry, focusing on competitive impacts and future strategies.

Insights from Utah's Doctronic AI Pilot: Early Data Analysis

This article delves into the early data from Utah's Doctronic AI pilot, highlighting key takeaways and implications for pharmaceutical teams.